ES2380047T3 - Composiciones y procedimientos para el tratamiento y prevención de la miocardiopatía y la enfermedad cardiaca - Google Patents

Composiciones y procedimientos para el tratamiento y prevención de la miocardiopatía y la enfermedad cardiaca Download PDF

Info

Publication number
ES2380047T3
ES2380047T3 ES06736222T ES06736222T ES2380047T3 ES 2380047 T3 ES2380047 T3 ES 2380047T3 ES 06736222 T ES06736222 T ES 06736222T ES 06736222 T ES06736222 T ES 06736222T ES 2380047 T3 ES2380047 T3 ES 2380047T3
Authority
ES
Spain
Prior art keywords
poloxamer
composition
subject
myocytes
see
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES06736222T
Other languages
English (en)
Spanish (es)
Inventor
Joseph Metzger
Dewayne Townsend
Soichiro Yasuda
Dan Michele
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Michigan System
University of Michigan Ann Arbor
Original Assignee
University of Michigan System
University of Michigan Ann Arbor
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Michigan System, University of Michigan Ann Arbor filed Critical University of Michigan System
Application granted granted Critical
Publication of ES2380047T3 publication Critical patent/ES2380047T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A61K31/77—Polymers containing oxygen of oxiranes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
ES06736222T 2005-02-25 2006-02-27 Composiciones y procedimientos para el tratamiento y prevención de la miocardiopatía y la enfermedad cardiaca Expired - Lifetime ES2380047T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US65657005P 2005-02-25 2005-02-25
US656570P 2005-02-25
PCT/US2006/006862 WO2006091941A2 (en) 2005-02-25 2006-02-27 Compositions and methods for treating and preventing cardiomyopathy and heart disease

Publications (1)

Publication Number Publication Date
ES2380047T3 true ES2380047T3 (es) 2012-05-08

Family

ID=36928113

Family Applications (1)

Application Number Title Priority Date Filing Date
ES06736222T Expired - Lifetime ES2380047T3 (es) 2005-02-25 2006-02-27 Composiciones y procedimientos para el tratamiento y prevención de la miocardiopatía y la enfermedad cardiaca

Country Status (8)

Country Link
US (2) US7846426B2 (https=)
EP (1) EP1853280B1 (https=)
JP (1) JP5042041B2 (https=)
AT (1) ATE546147T1 (https=)
AU (2) AU2006216420B2 (https=)
CA (1) CA2599219C (https=)
ES (1) ES2380047T3 (https=)
WO (1) WO2006091941A2 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2046348B1 (en) * 2006-08-01 2015-07-22 Phrixus Pharmaceuticals, Incorporated Use of poloxamer for the prevention and/or treatment of heart failure
WO2008124088A2 (en) * 2007-04-05 2008-10-16 Phrixus Pharmaceuticals, Inc. Compositions and methods for the treatment of heart failure
WO2009070793A1 (en) * 2007-11-29 2009-06-04 Pluromed, Inc. Endoscopic mucosal resectioning using purified inverse thermosensitive polymers
US8852568B2 (en) 2007-12-17 2014-10-07 The Regents Of The University Of Michigan Compositions and methods for treating and preventing skeletal muscle deficiencies
US9867547B2 (en) 2012-11-29 2018-01-16 Siemens Healthcare Gmbh System and method to calculate cardiac characteristics
WO2015050581A1 (en) * 2013-04-19 2015-04-09 Cedars-Sinai Medical Center Phosphodiesterase 5a inhibitors for the treatment of muscular dystrophy
EP3057598A1 (en) * 2013-10-16 2016-08-24 Mast Therapeutics, Inc. Diuretic induced alterations of plasma volume
US9757411B2 (en) 2014-07-07 2017-09-12 Aires Pharmaceuticals, Inc. Poloxamer therapy for heart failure
JP6747748B2 (ja) 2014-07-07 2020-08-26 ライフラフト バイオサイエンシーズ，インコーポレイテッド 長期循環物質のないポロクサマー組成物、その産生方法およびその使用
WO2016007542A1 (en) 2014-07-07 2016-01-14 Mast Therapeutics, Inc. Poloxamer therapy for heart failure
US20220023333A1 (en) * 2019-05-06 2022-01-27 Elena Valentinovna ARSHINTSEVA Method for increasing cancer patient's haemoglobin level

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2140408T3 (es) 1991-03-19 2000-03-01 Cytrx Corp Copolimeros de polioxipropileno/polioxietileno con actividad biologica mejorada.
JPH05178760A (ja) 1991-06-03 1993-07-20 Alpha Therapeutic Corp 心筋梗塞治療剤
US5994348A (en) * 1995-06-07 1999-11-30 Sanofi Pharmaceutical compositions containing irbesartan
US6761824B2 (en) 2000-08-17 2004-07-13 Reeve Lorraine E Process for the fractionation of polymers
WO2002065834A2 (en) * 2000-10-24 2002-08-29 Smithkline Beecham Corporation Novel formulations of carvedilol

Also Published As

Publication number Publication date
ATE546147T1 (de) 2012-03-15
JP5042041B2 (ja) 2012-10-03
CA2599219A1 (en) 2006-08-31
AU2010214636A1 (en) 2010-09-16
US20110044935A1 (en) 2011-02-24
CA2599219C (en) 2011-09-20
JP2008531598A (ja) 2008-08-14
WO2006091941A2 (en) 2006-08-31
EP1853280B1 (en) 2012-02-22
US7846426B2 (en) 2010-12-07
EP1853280A4 (en) 2008-10-29
US20080260681A1 (en) 2008-10-23
US8580245B2 (en) 2013-11-12
AU2006216420A1 (en) 2006-08-31
EP1853280A2 (en) 2007-11-14
WO2006091941A3 (en) 2007-01-04
AU2006216420B2 (en) 2010-07-15

Similar Documents

Publication Publication Date Title
US8580245B2 (en) Compositions and methods for treating and preventing cardiomyopathy and heart disease
AU2020323687B2 (en) MEK inhibitor for treatment of stroke
ES2532595T3 (es) Composición farmacéutica que contiene una nanopartícula de estatina encapsulada
ES2756776T3 (es) Formulación farmacéutica acuosa de tapentadol para administración oral
RU2503453C2 (ru) Фармацевтические композиции, обладающие желаемой биодоступностью
JP5560201B2 (ja) 骨格筋欠損症を治療および予防するための組成物および方法
ES2673009T3 (es) Plataforma de suministro tópico de microemulsiones
ES2976358T3 (es) Composiciones farmacéuticas oftálmicas exentas de conservantes
US9155758B2 (en) Treatment of chronic progressive heart failure
ES2906262T3 (es) Composiciones para el tratamiento de la autodigestión
BR112019012299A2 (pt) formulações farmacêuticas para o tratamento de glaucoma e métodos para a fabricação e uso das mesmas
ES3057657T3 (en) Biphenyl sulfonamide compounds for the treatment of type iv collagen diseases
ES2728071T3 (es) Composiciones oftalmológicas y su uso
US20080200563A1 (en) Use of Compounds Containing Thiol Groups as Efflux Pump Inhibitors
TW201521786A (zh) 胺碘酮類似物（ｂｕｄｉｏｄａｒｏｎｅ）調配物
BG64457B1 (bg) Фармацевтична форма за орално приложение, съдържаща hiv протеазен инхибитор
US20170022179A1 (en) Compositions, dosages, and methods of using tetrahydrocannabinol derivatives
WO2005037230A2 (en) Compositions and methods for treating heart failure
EP3972599A1 (en) Combination for lowering serum phosphate in a patient
US20110212883A1 (en) Radical scavenger and active oxygen eliminating agent
RU2700416C1 (ru) Способ профилактики соматических осложнений в интра- и послеоперационном периоде у пациентов с эндопротезированием тазобедренного и коленного суставов
JP4733348B2 (ja) 心不全、他の加齢関連臓器機能不全および加齢関連障害の予防のための、ならびに寿命を延長するための、ナトリウム−水素交換阻害剤であるカリポライドとａｃｅ阻害剤との組み合わせ製剤
BR112017006057A2 (pt) composição farmacêutica a base de prostaglandina j2 incorporada em sistemas micelares baseados em poloxâmero para potencialização das atividades analgésica e anti-inflamatória
SK284244B6 (sk) Farmaceutický prostriedok na liečenie HIV infekcie na orálne podanie